Abstract
Ras mutations occur at high frequency in thyroid cancer. In vitro, the effects of Ras in thyroid cells are pleiotropic in that expression of activated Ras has been reported to stimulate proliferation and apoptosis. An understanding of the factors that contribute to the survival versus demise of Ras-transformed cells is essential to our understanding of the contribution of Ras to thyroid neoplasia and other cancers. Constitutive expression of oncogenic H-Ras sensitized Wistar rat thyroid (WRT) cells to apoptosis stimulated by multiple insults. When deprived of matrix attachment, Ras-transformed cells perished by apoptotic cell death at a high frequency. In contrast, parental cells were more resistant to suspension-induced cell death. Ras effects on anchorage-independent cell death were reproduced by a mutant protein that signals selectively to Raf-1, but not by mutant Ras that preferentially binds to RalGDS. Expression of a Ras mutant that selectively activates PI3K resulted in substantial protection from detachment-induced cell death. MAPK activity was increased in adherent Ras12V- and Ras12V35S-expressing cells, but abolished upon detachment. Interestingly, impaired MAPK activity was sufficient to stimulate apoptosis in adherent Ras-transformed cells, but not in parental cells. Treatment with a PI3K inhibitor also stimulated apoptosis selectively in Ras-transformed cells. These results demonstrate that constitutive expression of activated Ras elicits differential effects on the survival of thyroid cells. Moreover, Ras expression results in a greater dependence of thyroid cells on MAPK and PI3K activity for their survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arscott P, Knapp J, Rymaszewski M, Barton J, Bretz J, Thompson N, Baker J . 1997 Endocrinol 138: 5019–5027
Avvedimento V, Monticelli A, Tramontano D, Polistina C, Nitsch L, Lauro RD . 1985 Eur. J. Biochem. 149: 467–472
Avvedimento VE, Musti AM, Ueffing M, Obici S, Gallo A, Sanchez M, DeBrasi D, Gottesman ME . 1991 Genes Dev. 5: 22–28
Berlingieri M, Akamizu T, Fusco A, Grieco M, Colletta G, Cirafici A, Ikuyama S, Kohn L, G V . 1990 Biochem. Biophys. Res. Commun. 173: 172–178
Bond J, Dawson T, Lemoine N, Wynford-Thomas D . 1992 Mol. Carcinogenesis 5: 129–135
Bond J, Wyllie F, Rowson J, Radulescu A, Wynford-Thomas D . 1994 Oncogene 9: 281–290
Bretz J, Rymaszewski M, Arscott PL, Myc A, Ain KB, Thompson NW, Baker Jr JR . 1999 J. Biol. Chem. 274: 23627–23632
Burns J, Blaydes J, Wright P, Lemoine L, Bond J, Williams E, Wynford-Thomas D . 1992 Mol. Carcinogenesis 6: 129–139
Cass LA, Meinkoth JL . 2000 Oncogene 19: 924–932
Cass LA, Summers SA, Prendergast GV, Backer JM, Birnbaum MJ, Meinkoth JL . 1999 Mol. Cell. Biol. 19: 5882–5891
Di Matola T, Mueller F, Fenzi G, Rossi G, Bifulco M, Marzano L, Vitale M . 2000 J. Clin. Endocrinol. Metab. 85: 1188–1193
Dremier S, Golstein J, Mosselmans R, Dumont JE, Galand P, Robaye B . 1994 Biochem. Biophys. Res. Comm. 200: 52–58
Francis-Lang H, Zannini M, Felice MD, Berlingieri M, Fusco A, Lauro RD . 1992 Mol. Cell. Biol. 12: 5793–5800
Frisch SM, Francis H . 1994 J. Cell. Biol. 124: 793–799
Fusco A, Berlinghieri MT, Fiore PPD, Portella G, Grieco M, Vecchio G . 1987 Mol. Cel. Biol. 7: 3365–3370
Gire V, Marshall C, Wynford-Thomas D . 1999 Oncogene 18: 4819–4832
Gire V, Wynford-Thomas D . 2000 Oncogene 19: 737–744
Gire V, Marshall C, Wynford-Thomas D . 2000 Oncogene 19: 2269–2276
Jeso BD, Ulianich L, Racioppi L, D'Armient F, Feliciello A, Pacifico F, Consiglio E, Formisano S . 1995 Biochem. Biophys. Res. Comm. 214: 819–824
Joneson T, White MA, Wigler MH, Bar-Sagi D . 1996 Science 271: 810–812
Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G . 1997 Nature 385: 544–548
Khwaja A, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J . 1997 EMBO. J. 16: 2783–2793
Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Noda M . 1989 Cell 56: 77–84
Kupperman E, Wofford D, Wen W, Meinkoth JL . 1996 Endocrinol. 137: 96–104
Lemoine NR, Staddon S, Bond J, Wyllie FS, Shaw JJ, Wynford-Thomas D . 1990 Oncogene 5: 1833–1837
Li X, Lu S, Miyagi E, Katoh R, Kawaoi A . 1999 Endocrinol. 140: 5962–5970
Lin T, Chen Q, Howe A, Juliano R . 1997 J. Biol. Chem. 272: 8849–8852
Maly FE, Quilliam LA, Dorseuil O, Der CJ, Bokoch GM . 1994 J. Biol. Chem. 269: 18743–18746
Miller MJ, Rioux L, Prendergast GV, Cannon S, White MA, Meinkoth JL . 1998 Mol. Cell. Biol. 18: 3718–3726
Missero C, Pirro M, Lauro RD . 2000 Mol. Cell. Biol. 20: 2783–2793
Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA . 1990 J. Clin. Endocrinol. Metab. 71: 223–229
Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J . 1997 Cell 89: 457–467
Saavedra H, Knauf J, Shirokawa J, Wang J, Ouyang B, Elisei R, Stambrook P, Fagin J . 2000 Oncogene 19: 3948–3954
Shirokawa JM, Elisei R, Knauf JA, Hara T, Wang J, Saavedra HI, Fagin JA . 2000 Mol. Endo. 14: 1725–1738
Suarez H, Villard JD, MCaillou BS, Schlumberger M, Tubiana M, Parmentier C, Monier R . 1990 Oncogene 5: 565–570
Tsygankova OM, Kupperman E, Wen W, Meinkoth JL . 2000 Oncogene 19: 3609–3615
Tsygankova OM, Saavedra A, Rebhun JF, Quilliam LA, Meinkoth JL . 2001 Mol. Cell. Biol. 21: 1921–1929
Vitale M, Matola TD, Bifulco M, Casamassima A, Fenzi G, Rossi G . 1999 FEBS Lett. 462: 57–60
White MA, Nicolette C, Minden A, Polverino A, Aelst LV, Karin M, Wigler MH . 1995 Cell 80: 533–541
Acknowledgements
We wish to acknowledge Gregory Prendergast for technical assistance and Dr Oxana Tysgankova for helpful suggestions and comments. This work was funded by PHS grant DK55757 to J Meinkoth.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cheng, G., Meinkoth, J. Enhanced sensitivity to apoptosis in Ras-transformed thyroid cells. Oncogene 20, 7334–7341 (2001). https://doi.org/10.1038/sj.onc.1204928
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204928
Keywords
This article is cited by
-
HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway
Journal of Molecular Medicine (2006)
-
Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways
Oncogene (2004)
-
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes
Oncogene (2003)
-
Role of cAMP, PKA and Rap1A in thyroid follicular cell survival
Oncogene (2002)